



RECEIVED

SEP 20 2002

1636

Attorney Docket No.: 6210.200-US

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#8

In re Application of: Andersen et al.

Serial No.: 10/002,826

Group Art Unit: To be assigned

Filed: November 30, 2001

Examiner: To be assigned

Confirmation No.: 7631

For: Production of Heterologous Polypeptides in Yeast

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on September 12, 2002.

Dolly Kapadia  
(name of person mailing paper)

Dolly Kapadia  
(signature of person mailing paper)



Attorney Docket No.: 6210.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Application No.: 10/002,826

Group Art Unit: To be assigned

Filed: November 30, 2001

Examiner: To be assigned

Confirmation No.: 7631

For: Production of Heterologous Polypeptides in Yeast

RECEIVED  
SEP 20 2002  
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:


1. WO 98/26079;
2. DE 195 25 282 A1;
3. Suissa et al., The EMBO Journal, Vol. 3, No. 8, pgs. 1773-1781 (1984);
4. Bloxham et al., Mol. Gen. Genet, Vol. 191, pgs. 499-506 (1983).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: September 12, 2002

  
\_\_\_\_\_  
Reza Green, Reg. No. 38,475  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800